Your browser doesn't support javascript.
loading
Feasibility of precision smoking treatment in a low-income community setting: results of a pilot randomized controlled trial in The Southern Community Cohort Study.
Lee, Scott S; Senft Everson, Nicole; Sanderson, Maureen; Selove, Rebecca; Blot, William J; King, Stephen; Gilliam, Karen; Kundu, Suman; Steinwandel, Mark; Sternlieb, Sarah J; Cai, Qiuyin; Warren Andersen, Shaneda; Friedman, Debra L; Connors Kelly, Erin; Fadden, Mary Kay; Freiberg, Matthew S; Wells, Quinn S; Canedo, Juan; Tyndale, Rachel F; Young, Robert P; Hopkins, Raewyn J; Tindle, Hilary A.
Affiliation
  • Lee SS; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA. scott.lee@vumc.org.
  • Senft Everson N; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Sanderson M; Meharry Medical College, Nashville, TN, USA.
  • Selove R; Tennessee State University, Nashville, TN, USA.
  • Blot WJ; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • King S; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Gilliam K; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Kundu S; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Steinwandel M; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Sternlieb SJ; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Cai Q; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Warren Andersen S; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Friedman DL; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
  • Connors Kelly E; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Fadden MK; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Freiberg MS; Meharry Medical College, Nashville, TN, USA.
  • Wells QS; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Canedo J; Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA.
  • Tyndale RF; Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
  • Young RP; Meharry Medical College, Nashville, TN, USA.
  • Hopkins RJ; Centre for Addiction and Mental Health, and Departments of Pharmacology & Toxicology, and Psychiatry, Campbell Family Mental Health Research Institute, University of Toronto, Toronto, ON, Canada.
  • Tindle HA; University of Auckland, Auckland, New Zealand.
Addict Sci Clin Pract ; 19(1): 16, 2024 03 15.
Article in En | MEDLINE | ID: mdl-38491559
ABSTRACT

BACKGROUND:

The feasibility of precision smoking treatment in socioeconomically disadvantaged communities has not been studied.

METHODS:

Participants in the Southern Community Cohort Study who smoked daily were invited to join a pilot randomized controlled trial of three smoking cessation

interventions:

guideline-based care (GBC), GBC plus nicotine metabolism-informed care (MIC), and GBC plus counseling guided by a polygenic risk score (PRS) for lung cancer. Feasibility was assessed by rates of study enrollment, engagement, and retention, targeting > 70% for each. Using logistic regression, we also assessed whether feasibility varied by age, sex, race, income, education, and attitudes toward precision smoking treatment.

RESULTS:

Of 92 eligible individuals (79.3% Black; 68.2% with household income < $15,000), 67 (72.8%; 95% CI 63.0-80.9%) enrolled and were randomized. Of these, 58 (86.6%; 95% CI 76.4-92.8%) engaged with the intervention, and of these engaged participants, 43 (74.1%; 95% CI 61.6-83.7%) were retained at 6-month follow-up. Conditional on enrollment, older age was associated with lower engagement (OR 0.83, 95% CI 0.73-0.95, p = 0.008). Conditional on engagement, retention was significantly lower in the PRS arm than in the GBC arm (OR 0.18, 95% CI 0.03-1.00, p = 0.050). No other selection effects were observed.

CONCLUSIONS:

Genetically informed precision smoking cessation interventions are feasible in socioeconomically disadvantaged communities, exhibiting high enrollment, engagement, and retention irrespective of race, sex, income, education, or attitudes toward precision smoking treatment. Future smoking cessation interventions in this population should take steps to engage older people and to sustain participation in interventions that include genetic risk counseling. TRIAL REGISTRATION ClinicalTrials.gov No. NCT03521141, Registered 27 April 2018, https//www. CLINICALTRIALS gov/study/NCT03521141.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Smoking / Tobacco Smoking Limits: Aged / Female / Humans / Male Language: En Journal: Addict Sci Clin Pract Journal subject: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Smoking / Tobacco Smoking Limits: Aged / Female / Humans / Male Language: En Journal: Addict Sci Clin Pract Journal subject: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Year: 2024 Document type: Article Affiliation country:
...